drugset / Trial / NCT01216241
Daptomycin Versus Placebo in Patients With Neutropenia and Fever
Phase 3
Terminated
36 enrolled
University of Rochester
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the benefits and side effects of daptomycin compared to placebo for the treatment of neutropenic fever.
Timeline
- Start
- 2011-04
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daptomycin | Other / unclassified | 8 mg/kg | Intravenous |